Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Preeclampsia

Nitric Oxide Formation Is Inversely Related to Serum Levels of Antiangiogenic Factors Soluble Fms-Like Tyrosine Kinase-1 and Soluble Endogline in Preeclampsia

Valeria C. Sandrim, Ana C.T. Palei, Ingrid F. Metzger, Valeria A. Gomes, Ricardo C. Cavalli, Jose E. Tanus-Santos
Download PDF
https://doi.org/10.1161/HYPERTENSIONAHA.108.115006
Hypertension. 2008;52:402-407
Originally published July 23, 2008
Valeria C. Sandrim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana C.T. Palei
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingrid F. Metzger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valeria A. Gomes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricardo C. Cavalli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose E. Tanus-Santos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Deficient NO formation has been implicated in hypertensive disorders of pregnancy. However, no previous study has compared the circulating nitrite concentrations in healthy pregnant women with those found in hypertensive disorders of pregnancy. Moreover, 2 antiangiogenic factors produced in the placenta (soluble fms-like tyrosine kinase-1 and soluble endogline) may affect NO formation during pregnancy. Here, we hypothesized that lower concentrations of markers of NO formation exist in hypertensive disorders of pregnancy and that inverse relationships exist between these markers and soluble fms-like tyrosine kinase-1 or soluble endogline. In this cross-sectional study, we compared 58 healthy pregnant women with 56 gestational hypertensive subjects and 45 preeclamptic patients. We measured plasma and whole blood nitrite concentrations using an ozone-based chemiluminescence assay and serum soluble fms-like tyrosine kinase-1 and soluble endogline concentrations using enzyme immunoassays. Whole blood nitrite levels were significantly lower in gestational hypertensive subjects and preeclamptic patients (−36% and −58%, respectively; both P<0.05) compared with healthy pregnant women. The plasma nitrite levels were ≈37% lower in both groups with hypertensive disorders of pregnancy compared with the group with normotensive pregnancies (both P<0.05). As expected, we found higher circulating soluble fms-like tyrosine kinase-1 and soluble endogline concentrations in preeclampsia compared with gestational hypertensive subjects or with healthy pregnancies (both P<0.05). We found negative correlations between antiangiogenic factors and plasma or whole blood nitrite concentrations (Spearman’s r from −0.175 to −0.226; all P<0.05). Our results show clinical evidence for impaired NO formation in preeclampsia or gestational hypertension. The negative correlations between markers of NO formation and antiangiogenic factors in preeclamptic patients suggest an inhibitory effect for these factors on NO formation.

  • NO
  • nitrite
  • whole blood nitrite
  • preeclampsia
  • sEng
  • sFLT-1

Normal human pregnancy is accompanied by increased blood volume that is accommodated within the cardiovascular system by systemic vasodilatation.1 This vasodilatation involves increased NO formation, thus decreasing peripheral vascular resistance in healthy pregnant women.2,3 On the other hand, deficient NO formation has been implicated in hypertensive disorders of pregnancy, such as preeclampsia and gestational hypertension.4–7 Indeed, previous studies compared the circulating concentrations of NO metabolites (nitrite+nitrate) in the plasma from preeclamptic women with those found in healthy pregnant women.8–13 Conflicting results were reported, and some studies showed higher,14 similar,10,12 or lower8 nitrite+nitrate levels in preeclamptic women compared with healthy pregnant women. A possible explanation for these discrepancies is that nitrite+nitrate may not accurately reflect endogenous NO formation in vivo, and there is mounting evidence that measuring the circulating concentrations of nitrite is an improved alternative to assess endogenously produced NO.15–19 However, no previous study has compared the circulating nitrite concentrations in healthy pregnant women with those found in women with preeclampsia.

The pathophysiology of preeclampsia is not completely known. However, there is evidence that a failure of cytotrophoblast invasion and absence of dilatation of uterine arteries lead to a high-resistance uteroplacental circulation, thus reducing placental perfusion and causing hypoxia, which, in turn, induces the release of factors to the maternal circulation that causes systemic endothelial dysfunction.20–22 Two important antiangiogenic factors produced in the placenta gain access to the maternal circulation and are involved in the pathogenesis of preeclampsia.23–25 First, soluble fms-like tyrosine kinase-1 (sFLT-1) is a splice variant of the vascular endothelial growth factor receptor that captures vascular endothelial growth factor,26,27 thus preventing its interaction with ligands and downregulating the biological effects of vascular endothelial growth factor, such as angiogenesis28 and stimulation of NO synthesis by endothelial cells.29–31 Second, although soluble endogline (sEng) is found in healthy pregnancies, its concentrations increase in preeclampsia. This is relevant because sEng is a transforming growth factor (TGF)-β1 and -β3 coreceptor that is highly expressed in vascular endothelial cells32 and may inhibit TGF-β1 signaling in the vasculature.33,34 Interestingly, endoglin modulates endothelial NO synthase (eNOS) expression and activity, thus affecting vascular tone.35–37

In the present study, we hypothesized that lower concentrations of relevant markers of NO formation (plasma and whole blood nitrite) would be found in hypertensive disorders of pregnancy compared with those found in healthy pregnancies. In addition, given the fact that sFLT-1 and sEng interfere with eNOS activity, we hypothesized that inverse relationships exist between the circulating concentrations of markers of NO formation and sFLT-1 or sEng during pregnancy.

Materials and Methods

Subjects

Approval for the use of human subjects was obtained from the institutional review board at the Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, and subjects gave informed consent. The procedures followed were in accordance with institutional guidelines. A total of 159 pregnant were enrolled in the University Hospital of the Faculty of Medicine of Ribeirao Preto Department of Obstetrics and Gynecology. Of these, 58 were healthy pregnant women with uncomplicated pregnancies, 56 were gestational hypertensive subjects, and 45 had preeclampsia. Hypertensive disorders were defined in accordance with the guidelines of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy.38 Gestational hypertension was defined as pregnancy-induced hypertension (≥140 mm Hg systolic or ≥90 mm Hg diastolic on ≥2 measurements ≥6 hours apart) without significant proteinuria in a woman after 20 weeks of gestation and returning to normal by 12 weeks postpartum. Preeclampsia was defined as increased blood pressure with significant proteinuria (≥0.3 g/24 hours) in a woman after 20 weeks of gestation. No women with preexisting hypertension, with or without superimposed preeclampsia, were included in the present study. Exclusion criteria included twin or multiple pregnancies or any evidence of previous medical illness.

At the time of clinic attendance, maternal venous blood samples were collected into standard Vacutainer tubes (Becton-Dickinson) containing heparin or clot activator (serum). The tubes were immediately centrifuged at 1000g for 3 minutes at room temperature, and plasma/serum samples were stored at −70°C until used to measure plasma nitrite and serum sFLT-1 and sEng concentrations. An aliquot of whole blood was mixed with a nitrite preservation solution in a 4:1 dilution, as described previously,39–41 and stored at −70°C until analyzed to measure whole blood nitrite concentrations. Briefly, this solution contains 0.8 mol/L of ferricyanide and 1% Nonidet P-40.39–41

Enzyme Immunoassays of Angiogenic Factors

Serum concentrations of sFLT-1 and sEng were measured with commercially available ELISA kits (R&D Systems) according to the manufacturer’s instructions.

Measurement of Plasma and Whole Blood Nitrite Concentrations

Plasma aliquots were analyzed in triplicate for their nitrite content using an ozone-based chemiluminescence assay, as described previously.42–45 Briefly, 200 μL of plasma samples were injected into a solution of acidified triiodide, purging with nitrogen in-line with a gas-phase chemiluminescence NO analyzer (Sievers Model 280 NO Analyzer). Approximately 8 mL of triiodide solution (2.0 g of potassium iodide and 1.3 g of iodine dissolved in 40 mL of water with 140 mL of acetic acid) were placed in the purge vessel into which plasma samples were injected. The triiodide solution reduced nitrites to NO gas, which was detected by the NO analyzer.

To measure whole blood nitrite concentrations in triplicate, whole blood samples were deproteinated with methanol (1:1) and centrifuged at 14 000g for 3 minutes. Then, 300 μL of supernatant were injected into the solution of acidified triiodide and purged with nitrogen in-line with a gas-phase chemiluminescence NO analyzer, as described above.

Statistical Analysis

Data were reported as the means±SEMs. The clinical and biochemical characteristics of study groups were compared, respectively, by 1-way ANOVA followed by the Dunnett multiple comparisons test, and by the Kruskal-Wallis test followed by the Dunn’s multiple comparison test. The correlations among plasma or whole blood nitrite concentrations and sFLT-1 or sEng concentrations were analyzed using Spearman’s correlation (rs and P values). Statistical analysis was performed with StatView for Windows. A P value of <0.05 was considered the minimum level of statistical significance.

Results

The Table summarizes the clinical characteristics of the 159 subjects enrolled in the present study. There were no significant differences in age, gestational age at sampling, and percentage of primigravida between the hypertensive groups and the control (healthy) group (all P>0.05). However, women with gestational hypertension had higher body mass index than those in the other groups (P<0.05; Table). As expected, higher systolic and diastolic blood pressures were found in women with gestational hypertension or with preeclampsia compared with the control group (both P<0.05; Table). Lower birth weights and gestational ages at delivery were found in the group of preeclamptic women compared with the other groups (P<0.05; Table).

View this table:
  • View inline
  • View popup

Table. Characteristics of Study Participants

Whole blood nitrite levels were significantly lower in the gestational hypertensive subjects and preeclamptic patients (−36% and −58%, respectively; both P<0.05; Figure 1) compared with those found in healthy pregnancies. The plasma nitrite levels were ≈37% lower in both groups of hypertensive pregnancies compared with the group of normotensive pregnancies (both P<0.05; Figure 1). As expected,34,46–50 we found higher circulating sFLT-1 and sEng concentrations in preeclampsia compared with gestational hypertensive subjects or with healthy pregnancies (both P<0.05; Figure 2).

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Whole blood (A) and plasma (B) nitrite levels in healthy pregnant (HP), gestational hypertensive subjects (GH), and patients with preeclampsia (PE). The bars indicate the means±SEMs. *P<0.05 and **P<0.01 vs healthy pregnant subjects.

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Serum sFLT-1 (A) and sEng (B) concentrations in healthy pregnant (HP), gestational hypertensive subjects (GH), and patients with preeclampsia (PE). The bars indicate the means± SEMs. *P<0.05 and **P<0.01 vs healthy pregnant subjects.

To address the possibility that inverse relationships exist between the circulating concentrations of markers of NO formation and sFLT-1 or sEng, we carried out correlation analysis between sFLT-1 or sEng levels and whole blood or plasma nitrite concentrations. Taking into consideration all of the pregnant women, we found significant negative correlations between both antiangiogenic factors and plasma nitrite or whole blood nitrite concentrations (Figure 3; all P<0.05). Interestingly, when we excluded gestational hypertensive women from the analysis, the correlations strengthened even more.

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 3. Correlations between whole blood (A and C) or plasma nitrite levels (B and D) and sFLT-1 (A and B) or sEng concentrations (C and D) in healthy pregnant (○), gestational hypertensive (•), and preeclamptic (▵) women. The regression line and the 95% CI are plotted. P and Spearman’s correlation (r) values are reported.

When we examined whether significant correlations exist between these markers and the severity of preeclampsia, we found that proteinuria correlated significantly with both sFLT-1 and sEng (r=0.490, P=0.002, and r=0.621, P<0.0001, respectively), but not with whole blood or plasma nitrite (both P>0.05). In addition, systolic and diastolic blood pressures correlated significantly with sEng (r=0.5310, P<0.0001, and r=0.353, P=0.008, respectively) but not with other markers (all P>0.05).

Discussion

This is the first study to measure the circulating nitrite levels in hypertensive disorders of pregnancy. A main novel finding reported here is that patients with preeclampsia or with gestational hypertension have lower whole blood and lower plasma nitrite levels compared with normotensive healthy pregnant women, thus indicating impaired NO formation during hypertensive pregnancies. Moreover, our findings suggest that the circulating concentrations of these markers of NO formation correlate negatively with the increased circulating levels of the antiangiogenic factors sFLT-1 and sEng, a usual finding during preeclampsia.34,46–50

Important changes in maternal cardiovascular hemodynamics take place during normal pregnancy. These modifications include increased blood volume and cardiac output without increases in arterial blood pressure, and 1 of the main reasons for the lack of increase in arterial blood pressure during normal pregnancy is NO-induced systemic vascular dilation.2 Although impaired NO formation has been implicated in the pathogenesis of hypertensive disorders of pregnancy,4–7 no previous study has examined whether these conditions downregulate the circulating levels of relevant markers of NO formation. Because NO is rapidly oxidized to nitrite, recent studies have indicated that measuring plasma nitrite levels may reflect endogenous NO formation. This is because ≈70% of plasma nitrites derive from NO synthase activity in the endothelium,15 and inhibition of NO synthase activity was associated with corresponding decreases in circulation nitrite concentrations.15,17 The reduced concentrations of both plasma and whole blood nitrite give support to the idea that preeclampsia and gestational hypertension are disorders of pregnancy characterized by impaired NO formation.4–7

The antiangiogenic factors sFLT-1 and sEng have been widely studied in preeclampsia.46,49,51 Our results corroborate previous studies showing strikingly elevated sFLT-1 and sEng levels in preeclampsia compared with healthy pregnancies or with gestational hypertension.34,46–50 These factors probably play a role in the pathophysiology of preeclampsia and have been associated with endothelial dysfunction, which is usually found in this disorder.34,49 The impaired endothelial function could result from sFLT-1–induced antagonism of vascular endothelial growth factor actions,26,27 which include eNOS activation via phosphorylation of Ser-1177 by Akt52 and NO synthesis by endothelial cell.29–31 In fact, our findings showing an inverse correlation between plasma or whole blood nitrite concentrations and sFLT-1 levels are consistent with this suggestion and provide clinical evidence for a pathophysiological mechanism probably playing a role in preeclampsia.

Endoglin is a TGF-β1 and -β3 coreceptor highly expressed in vascular endothelial cells,32 and it may be cleaved in preeclampsia, thus releasing its extracellular domain into the circulation forming sEng. This soluble form of endoglin, in turn, decreases the arterial vasodilatation induced by TGF-β1 and -β3, which is mediated by NO. Indeed, TGF-β receptor activation increases NO formation through increased eNOS expression and activation,53,54 and sEng attenuates eNOS activation by TGF-β by interfering with the Thr495 dephosphorylation of eNOS, thus contributing to decreased NO synthesis.34 The negative correlations that we found between plasma or whole blood nitrite concentrations and sEng support the suggestion that sEng plays a role in the pathogenesis of preeclampsia by decreasing NO formation. Finally, it is possible that increased concentrations of asymmetrical dimethyl arginine (an endogenous NO synthesis inhibitor) contribute to decreased NO signaling in preeclampsia.55

In conclusion, we found clinical evidence for impaired NO formation in patients with preeclampsia or with gestational hypertension. Moreover, the negative correlations that we found between NO markers and sFLT-1 or sEng in preeclamptic patients suggest relevant mechanisms possibly involved in the pathogenesis of this life-threatening condition. These findings may have important therapeutic implications.

Perspectives

In this study, we show clinical evidence for impaired NO formation in patients with preeclampsia or with gestational hypertension. Importantly, the decreased concentrations of markers of NO formation were negatively associated with the circulating levels of relevant antiangiogenic factors produced in the placenta. Although these antiangiogenic factors have been implicated in the pathogenesis of preeclampsia, this is the first study reporting clinical evidence for a possible inhibitory effect caused by these factors on the endogenous formation of NO in patients with preeclampsia. These findings may have important therapeutic implications. Although the cause of upregulation of antiangiogenic factors in preeclampsia remains unknown, it is possible that therapeutic approaches focusing on upregulating NO bioavailability may be useful targets in patients with gestational disorders of pregnancy.

Acknowledgments

Sources of Funding

This study was funded by the Fundação de Amparo a Pesquisa do Estado de São Paulo and the Conselho Nacional de Desenvolvimento Científico e Tecnológico.

Disclosures

None.

  • Received April 16, 2008.
  • Revision received May 19, 2008.
  • Accepted May 29, 2008.

References

  1. ↵
    Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol. 1989; 256: H1060–H1065.
    OpenUrlPubMed
  2. ↵
    Sladek SM, Magness RR, Conrad KP. Nitric oxide and pregnancy. Am J Physiol. 1997; 272: R441–R463.
    OpenUrlPubMed
  3. ↵
    Williams DJ, Vallance PJ, Neild GH, Spencer JA, Imms FJ. Nitric oxide-mediated vasodilation in human pregnancy. Am J Physiol. 1997; 272: H748–H752.
    OpenUrlPubMed
  4. ↵
    Cockell AP, Poston L. Flow-mediated vasodilatation is enhanced in normal pregnancy but reduced in preeclampsia. Hypertension. 1997; 30: 247–251.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Kublickiene KR, Lindblom B, Kruger K, Nisell H. Preeclampsia: evidence for impaired shear stress-mediated nitric oxide release in uterine circulation. Am J Obstet Gynecol. 2000; 183: 160–166.
    OpenUrlPubMed
  6. ↵
    Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 2003; 361: 1511–1517.
    OpenUrlCrossRefPubMed
  7. ↵
    Garcia RG, Celedon J, Sierra-Laguado J, Alarcon MA, Luengas C, Silva F, Arenas-Mantilla M, Lopez-Jaramillo P. Raised C-reactive protein and impaired flow-mediated vasodilation precede the development of preeclampsia. Am J Hypertens. 2007; 20: 98–103.
    OpenUrlCrossRefPubMed
  8. ↵
    Aydin S, Benian A, Madazli R, Uludag S, Uzun H, Kaya S. Plasma malondialdehyde, superoxide dismutase, sE-selectin, fibronectin, endothelin-1 and nitric oxide levels in women with preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2004; 113: 21–25.
    OpenUrlCrossRefPubMed
  9. ↵
    D'Anna R, Baviera G, Corrado F, Crisafulli A, Ientile R, Buemi M, Squadrito F. Neurokinin B and nitric oxide plasma levels in pre-eclampsia and isolated intrauterine growth restriction. BJOG. 2004; 111: 1046–1050.
    OpenUrlPubMed
  10. ↵
    Schiessl B, Strasburger C, Bidlingmaier M, Mylonas I, Jeschke U, Kainer F, Friese K. Plasma- and urine concentrations of nitrite/nitrate and cyclic Guanosinemonophosphate in intrauterine growth restricted and preeclamptic pregnancies. Arch Gynecol Obstet. 2006; 274: 150–154.
    OpenUrlCrossRefPubMed
  11. ↵
    Yoneyama Y, Suzuki S, Sawa R, Miura A, Doi D, Otsubo Y, Araki T. Plasma nitric oxide levels and the expression of P-selectin on platelets in preeclampsia. Am J Obstet Gynecol. 2002; 187: 676–680.
    OpenUrlCrossRefPubMed
  12. ↵
    Conrad KP, Kerchner LJ, Mosher MD. Plasma and 24-h NO(x) and cGMP during normal pregnancy and preeclampsia in women on a reduced NO(x) diet. Am J Physiol. 1999; 277: F48–F57.
    OpenUrlPubMed
  13. ↵
    Norris LA, Higgins JR, Darling MR, Walshe JJ, Bonnar J. Nitric oxide in the uteroplacental, fetoplacental, and peripheral circulations in preeclampsia. Obstet Gynecol. 1999; 93: 958–963.
    OpenUrlCrossRefPubMed
  14. ↵
    Ranta V, Viinikka L, Halmesmaki E, Ylikorkala O. Nitric oxide production with preeclampsia. Obstet Gynecol. 1999; 93: 442–445.
    OpenUrlCrossRefPubMed
  15. ↵
    Kleinbongard P, Dejam A, Lauer T, Rassaf T, Schindler A, Picker O, Scheeren T, Godecke A, Schrader J, Schulz R, Heusch G, Schaub GA, Bryan NS, Feelisch M, Kelm M. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med. 2003; 35: 790–796.
    OpenUrlCrossRefPubMed
  16. ↵
    Lauer T, Preik M, Rassaf T, Strauer BE, Deussen A, Feelisch M, Kelm M. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci U S A. 2001; 98: 12814–12819.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Kelm M, Preik-Steinhoff H, Preik M, Strauer BE. Serum nitrite sensitively reflects endothelial NO formation in human forearm vasculature: evidence for biochemical assessment of the endothelial L-arginine-NO pathway. Cardiovasc Res. 1999; 41: 765–772.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Kleinbongard P, Dejam A, Lauer T, Jax T, Kerber S, Gharini P, Balzer J, Zotz RB, Scharf RE, Willers R, Schechter AN, Feelisch M, Kelm M. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med. 2006; 40: 295–302.
    OpenUrlCrossRefPubMed
  19. ↵
    Metzger IF, Sertorio JTC, Tanus-Santos JE. Relationship between systemic nitric oxide metabolites and cyclic GMP in healthy male volunteers. Acta Physiol. 2006; 188: 123–127.
    OpenUrlCrossRef
  20. ↵
    McCarthy AL, Woolfson RG, Raju SK, Poston L. Abnormal endothelial cell function of resistance arteries from women with preeclampsia. Am J Obstet Gynecol. 1993; 168: 1323–1330.
    OpenUrlPubMed
  21. ↵
    Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989; 161: 1200–1204.
    OpenUrlCrossRefPubMed
  22. ↵
    Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest. 1997; 99: 2152–2164.
    OpenUrlCrossRefPubMed
  23. ↵
    Hladunewich M, Karumanchi SA, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol. 2007; 2: 543–549.
    OpenUrlFREE Full Text
  24. ↵
    Baumwell S, Karumanchi SA. Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract. 2007; 106: c72–c81.
    OpenUrlCrossRefPubMed
  25. ↵
    Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res. 2008; 75: 1–8.
    OpenUrlCrossRefPubMed
  26. ↵
    Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun. 1996; 226: 324–328.
    OpenUrlCrossRefPubMed
  27. ↵
    Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct. 2001; 26: 25–35.
    OpenUrlCrossRefPubMed
  28. ↵
    Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis. 2006; 9: 225–230.
    OpenUrlCrossRefPubMed
  29. ↵
    He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem. 1999; 274: 25130–25135.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Kroll J, Waltenberger J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun. 1998; 252: 743–746.
    OpenUrlCrossRefPubMed
  31. ↵
    Shen BQ, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem. 1999; 274: 33057–33063.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992; 267: 19027–19030.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006; 355: 992–1005.
    OpenUrlCrossRefPubMed
  34. ↵
    Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006; 12: 642–649.
    OpenUrlCrossRefPubMed
  35. ↵
    Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, Husain M, Letarte M. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res. 2005; 96: 684–692.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Santibanez JF, Letamendia A, Perez-Barriocanal F, Silvestri C, Saura M, Vary CP, Lopez-Novoa JM, Attisano L, Bernabeu C. Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J Cell Physiol. 2007; 210: 456–468.
    OpenUrlCrossRefPubMed
  37. ↵
    Ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis. 2008; 11: 79–89.
    OpenUrlCrossRefPubMed
  38. ↵
    Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000; 183: S1–S22.
    OpenUrlCrossRefPubMed
  39. ↵
    Pelletier MM, Kleinbongard P, Ringwood L, Hito R, Hunter CJ, Schechter AN, Gladwin MT, Dejam A. The measurement of blood and plasma nitrite by chemiluminescence: pitfalls and solutions. Free Radic Biol Med. 2006; 41: 541–548.
    OpenUrlCrossRefPubMed
  40. ↵
    Nagassaki S, Sertorio JTC, Metzger IF, Bem AF, Rocha JBT, Tanus-Santos JE. eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic Biol Med. 2006; 41: 1044–1049.
    OpenUrlCrossRefPubMed
  41. ↵
    Dejam A, Hunter CJ, Pelletier MM, Hsu LL, Machado RF, Shiva S, Power GG, Kelm M, Gladwin MT, Schechter AN. Erythrocytes are the major intravascular storage sites of nitrite in human blood. Blood. 2005; 106: 734–739.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Metzger IF, Souza-Costa DC, Marroni AS, Nagassaki S, Desta Z, Flockhart DA, Tanus-Santos JE. Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genomics. 2005; 15: 565–570.
    OpenUrlPubMed
  43. ↵
    Nagassaki S, Metzger IF, Souza-Costa DC, Marroni AS, Uzuelli JA, Tanus-Santos JE. eNOS genotype is without effect on circulating nitrite/nitrate level in healthy male population. Thromb Res. 2005; 115: 375–379.
    OpenUrlCrossRefPubMed
  44. ↵
    Yang BK, Vivas EX, Reiter CD, Gladwin MT. Methodologies for the sensitive and specific measurement of S-nitrosothiols, iron-nitrosyls, and nitrite in biological samples. Free Radic Res. 2003; 37: 1–10.
    OpenUrlPubMed
  45. ↵
    Dias-Junior CA, Gladwin MT, Tanus-Santos JE. Low-dose intravenous nitrite improves hemodynamics in a canine model of acute pulmonary thromboembolism. Free Radic Biol Med. 2006; 41: 1764–1770.
    OpenUrlCrossRefPubMed
  46. ↵
    Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J Clin Endocrinol Metab. 2007; 92: 2672–2679.
    OpenUrlCrossRefPubMed
  47. ↵
    Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol. 2006; 194: 551–556.
    OpenUrlCrossRefPubMed
  48. ↵
    Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003; 188: 177–182.
    OpenUrlCrossRefPubMed
  49. ↵
    Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003; 111: 649–658.
    OpenUrlCrossRefPubMed
  50. ↵
    Levine RJ, Karumanchi SA. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol. 2005; 48: 372–386.
    OpenUrlCrossRefPubMed
  51. ↵
    Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhani R. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007; 50: 137–142.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    Dimmeler S, Dernbach E, Zeiher AM. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS letters. 2000; 477: 258–262.
    OpenUrlCrossRefPubMed
  53. ↵
    Inoue N, Venema RC, Sayegh HS, Ohara Y, Murphy TJ, Harrison DG. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1. Arterioscler Thromb Vasc Biol. 1995; 15: 1255–1261.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    Saura M, Zaragoza C, Cao W, Bao C, Rodriguez-Puyol M, Rodriguez-Puyol D, Lowenstein CJ. Smad2 mediates transforming growth factor-beta induction of endothelial nitric oxide synthase expression. Circ Res. 2002; 91: 806–813.
    OpenUrlAbstract/FREE Full Text
  55. ↵
    Pettersson A, Hedner T, Milsom I. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand. 1998; 77: 808–813.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
August 2008, Volume 52, Issue 2
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Nitric Oxide Formation Is Inversely Related to Serum Levels of Antiangiogenic Factors Soluble Fms-Like Tyrosine Kinase-1 and Soluble Endogline in Preeclampsia
    Valeria C. Sandrim, Ana C.T. Palei, Ingrid F. Metzger, Valeria A. Gomes, Ricardo C. Cavalli and Jose E. Tanus-Santos
    Hypertension. 2008;52:402-407, originally published July 23, 2008
    https://doi.org/10.1161/HYPERTENSIONAHA.108.115006

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Nitric Oxide Formation Is Inversely Related to Serum Levels of Antiangiogenic Factors Soluble Fms-Like Tyrosine Kinase-1 and Soluble Endogline in Preeclampsia
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Nitric Oxide Formation Is Inversely Related to Serum Levels of Antiangiogenic Factors Soluble Fms-Like Tyrosine Kinase-1 and Soluble Endogline in Preeclampsia
    Valeria C. Sandrim, Ana C.T. Palei, Ingrid F. Metzger, Valeria A. Gomes, Ricardo C. Cavalli and Jose E. Tanus-Santos
    Hypertension. 2008;52:402-407, originally published July 23, 2008
    https://doi.org/10.1161/HYPERTENSIONAHA.108.115006
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Cardiology
    • Etiology
      • Hypertension
        • Hypertension
  • Basic, Translational, and Clinical Research
    • Endothelium/Vascular Type/Nitric Oxide

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured